ArticleBMJ open gastroenterology2018

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Christopher Sj Probert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.